Biodesix announced strong Q1 2026 results with $25.6 million revenue, up 42% year-over-year, driven by a 29% increase in diagnostic test volumes and doubled Development Services revenue. The company improved gross margin to 84% and reduced net loss by 30%, signaling progress toward profitability. Biodesix raised its full-year 2026 revenue guidance to $108-114 million, expecting continued growth and operational leverage. This performance highlights Biodesix's expanding market presence and operational efficiency in diagnostic solutions.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
IPG Photonics announced a binding offer to acquire Lumibird Medical for €300 million, with an additional earnout of up to €50 million based on performance. This acquisition will expand IPG's Advanced Solutions portfolio in medical lasers, particularl...
Constellation Software Inc. announced it will hold a conference call and live webcast on August 12, 2026, at 8:00 a.m. ET to discuss its second quarter results. The company will release its quarterly earnings after the Toronto Stock Exchange closes o...
Kuehn Law, PLLC is investigating whether officers and directors of Quantum Computing Inc. breached their fiduciary duties through potential self-dealing. The investigation could lead to shareholder damages and corporate governance reforms. Long-term ...
